Subscribe
shutterstock_1862407378_ralf_liebhold
Ralf Liebhold / Shutterstock.com
6 July 2021GenericsAlex Baldwin

Teva sues two Indian generics over Huntington’s treatment

Teva Pharmaceuticals has filed lawsuits  in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Generics
Generics win anti-pay-for-delay bill challenge
14 December 2021   The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Generics
Amgen, Teva to face Sensipar monopoly claims
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Generics
Generics win anti-pay-for-delay bill challenge
14 December 2021   The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Generics
Amgen, Teva to face Sensipar monopoly claims
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

More on this story

Big Pharma
Teva settles patent dispute with Aurobindo
13 June 2022   Israel-headquartered Teva has settled its dispute with Indian generic maker Aurobindo over a drug used to treat Huntington’s disease.
Generics
Generics win anti-pay-for-delay bill challenge
14 December 2021   The Association for Accessible Medicines, which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.
Generics
Amgen, Teva to face Sensipar monopoly claims
3 December 2020   Amgen and Teva will have to face a lawsuit accusing them of restricting competition by engineering a reverse payment designed to keep generic versions of Sensipar off the market.

More features

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Mental health IP toolkit: Diversity Champ’s stress-busting tips
Eli Lilly piles on weight loss drug suits to ward off revenue squeeze
Patent cliff: 5 blockbusters running out of road
Herbert Smith Freehills expands German tech patent team
‘Always new twists’: Bayer legal team on defending a $4bn drug
Novartis and MSN feud intensifies after Fed Circ denies rehearing
EU court signals tough stance on ‘pay-for-delay’ pharma deals